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Abstract
Objectives: Epilepsy	has	been	associated	with	cardiovascular	comorbidity.	This	study	
aimed	to	assess	the	potential	association	between	cardiovascular	risk	factors	(CRFs),	
antiepileptic	drugs	(AEDs),	and	etiology.
Material and Methods: A	single-	center	retrospective	epilepsy	cohort	from	the	decade	
of	2004–2013	was	assessed.	Poisson	regression	models	with	 robust	variance	were	
estimated	 to	obtain	CRF	prevalence	 ratios	 (PR)	 according	 to	AED	prescription	 and	
etiology.
Results: After	excluding	patients	in	the	monotherapy	group	with	vascular	etiology	or	
previous	cardiovascular	events,	in	the	remaining	400	patients,	enzyme-	inducer	AEDs	
(EIAEDs),	especially	phenytoin	(PHT),	were	associated	with	higher	prevalence	of	dys-
lipidemia	(PRa	1.77,	p	<	.05),	compared	to	valproic	acid.	No	etiology	was	associated	
with	higher	prevalence	of	any	CRF.
Conclusions: Patients	treated	with	EIAEDs,	especially	PHT,	had	higher	prevalence	of	
dyslipidemia.
K E Y W O R D S
antiepileptic	drugs,	cardiovascular	risk	factors,	comorbidity,	epilepsy
1  | INTRODUCTION
Epilepsy	 is	 one	 of	 the	 most	 prevalent	 chronic	 neurologic	 disorders	
(World	Health	Organization,	2015).	Many	people	with	epilepsy	(PWE)	
receive	lifelong	prescription	treatment.
Older	 antiepileptic	 drugs	 (AEDs),	 mainly	 enzyme	 inducers	
(EIAEDs),	 such	 as	 carbamazepine	 (CBZ),	 phenytoin	 (PHT),	 pheno-
barbital	 (PB),	or	primidone,	may	be	associated	with	more	adverse	
effects	 than	 newer	 AEDs.	 For	 example,	 they	 alter	 lipid	 profile,	
increasing	serum	cholesterol	levels	(Mintzer	et	al.,	2009).	However,	
there	is	a	lack	of	information	about	the	prevalence	of	dyslipidemia	
related	 to	 the	 use	 of	 AEDs,	 which	 would	 facilitate	 appropriate	
management	to	reduce	the	risk	of	vascular	diseases.	Another	AED	
that	has	been	related	to	vascular	risk	factors	is	valproic	acid	(VPA),	
which	has	been	associated	with	metabolic	 syndrome	 (Kim	&	Lee,	
2007).	 For	 these	 reasons,	 some	 authors	 have	 suggested	 start-
ing	 new	 AEDs	 in	 newly	 diagnosed	 patients	 or	 changing	 EIAEDs	
if	 patients	 experience	 metabolism-	related	 effects	 (Brodie	 et	al.,	
2013).
Higher	 prevalence	 of	 cardiovascular	 risk	 factors	 (CRFs)	 such	 as	
hypertension,	 diabetes,	 and	 high	 cholesterol	 has	 been	 reported	 in	
PWE,	 compared	 to	 general	 population	 (Elliott	 et	al.,	 2009;	 Téllez-	
Zenteno,	Matijevic,	&	Wiebe,	2005).	A	recent	review	of	comorbidity	
in	 epilepsy	 (Gaitatzis,	 Sisodiya,	 &	 Sander,	 2012)	 suggested	 a	 causal	
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association	with	 hypertension	 and	 diabetes,	 both	 of	which	 are	 risk	
factors	 for	 stroke.	As	 cerebrovascular	 disease	 accounts	 for	 approxi-
mately	30%	of	newly	diagnosed	epilepsy	in	adults	(Hauser,	Annegers,	
&	Kurland,	1993),	 that	could	 reflect	 the	causal	association	between	
these	risk	factors	and	epilepsy.	Therefore,	more	information	is	needed	
to	 know	 if	 epilepsy	 itself—with	 an	 etiology	 other	 than	 vascular—is	
associated	with	CRFs.
Information	about	the	prevalence	of	CRFs	in	PWE	and	their	asso-
ciation	with	AED	use	or	etiology	is	crucial	to	the	management	of	vas-
cular	risk	in	these	patients.	The	specific	aim	of	the	study	was	to	assess	
whether	there	was	an	association	between	prescribed	AEDs,	epilepsy	
etiology,	and	classic	CRFs.
2  | MATERIAL AND METHODS
2.1 | Study population
Patients	included	in	the	study	were	part	of	EPIVASMAR,	a	hospital-	
based	outpatient	registry	of	Hospital	del	Mar.	The	outpatient	clinic	
of	 this	 university	 medical	 center	 serves	 a	 population	 of	 339,196	
inhabitants	 in	 the	 city	 of	 Barcelona	 and	 is	 the	 referral	 center	 for	
PWE.	EPIVASMAR	is	a	retrospective	register	of	PWE	recruited	from	
January	2004—when	electronic	medical	records	began	to	be	avail-
able—to	December	2013.	The	aims	of	the	register	were	to	describe	
CRF	distribution	and	prevalence	and	cardiovascular	events	in	PWE.	
A	standardized	data	collection	form	was	designed	to	collect	demo-
graphic	data,	epilepsy	characteristics	(type,	etiology,	duration,	AED	
treatment),	date	of	 inclusion	in	the	register	 (regardless	of	the	date	
of	epilepsy	diagnosis),	CRFs	at	inclusion,	and	cardiovascular	events.	
The	 register	 included	 only	 patients	 with	 a	 diagnosis	 of	 epilepsy	
according	to	the	2005	International	League	Against	Epilepsy	(ILAE)	
definition	(Fisher	et	al.,	2005).	To	identify	cases	for	this	study,	elec-
tronic	medical	 records	 of	 the	 patients	 attended	 in	 the	 outpatient	
clinic	with	a	diagnosis	of	epilepsy	were	revised	one-	by-	one	by	the	
principal	 investigator	 (RMVH).	 The	 international	 classification	 of	
diseases	 codification	 was	 not	 used	 because,	 at	 the	 time	 of	 data	
collection,	 it	 was	 not	 considered	 reliable.	 Etiology	 was	 assessed	
using	the	available	test	information	(CT,	MRI,	EEG)	and	classified	as	
genetic	(epilepsy	is	the	direct	result	of	a	known	or	presumed	genetic	
defect(s)	 in	which	seizures	are	 the	core	symptom	of	 the	disorder),	
structural/metabolic	(there	is	a	distinct	other	structural	or	metabolic	
condition	or	disease	that	has	been	demonstrated	to	be	associated	
with	an	increased	risk	of	developing	epilepsy),	and	unknown	cause	
(the	nature	of	the	underlying	cause	 is	as	yet	unknown;	Berg	et	al.,	
2010).	 Treatment	 at	 inclusion	was	 determined	 from	 prescriptions	
written	by	the	general	physician	(GP)	and	neurologist.	In	this	analy-
sis,	only	participants	older	than	35	years	were	included.	The	register	
was	approved	by	the	 local	 institutional	ethics	committee	 (Hospital	
del	 Mar-	IMIM	 2014/5505/I)	 and	 followed	 national	 and	 interna-
tional	 guidelines	 (Deontological	 Code,	 Declaration	 of	 Helsinki).	
Written	 informed	 consent	was	not	 required	 for	 this	 observational	
study.	Patient	 information	was	anonymized	and	de-	identified	prior	
to	analysis.
2.2 | Definition of cardiovascular risk factors
Diabetes	was	considered	 if	a	diagnosis	had	been	recorded	by	a	GP,	
the	 patient	was	 under	 treatment,	 or	 fasting	 glucose	was	 ≥126	mg/
dl	in	two	blood	tests	or	≥200	mg/dl	or	HbA1c	>6.5%	in	any	test	per-
formed	close	 to	 the	 inclusion	date.	Hypertension	was	considered	 if	
patients	were	diagnosed	by	a	GP,	were	under	treatment,	or	had	rest-
ing	 blood	 pressure	 measurements	 taken	 close	 to	 the	 study	 inclu-
sion	 date	 of	 systolic	 blood	 pressure	 ≥140	mmHg	 or	 diastolic	 blood	
pressure	 ≥90	mmHg.	Dyslipidemia	was	 considered	 if	 patients	were	
diagnosed	by	a	GP,	were	under	treatment,	or	fasting	total	cholesterol	
was	≥240	mg/dl	or	triglycerides	≥200	mg/dl	(De	Backer	et	al.,	2003).	
Smoking	was	recorded	as	current,	former,	and	never	smokers,	accord-
ing	to	the	electronic	medical	record.
2.3 | Statistical analysis
A	descriptive	analysis	of	the	variables	of	interest	was	performed	cal-
culating	 percentages	 in	 categorical	 and	 mean	 or	 median	 with	 cor-
responding	 standard	 deviations	 and	 interquartile	 range	 (depending	
on	normal	distribution)	 in	quantitative	variables.	A	bivariate	analysis,	
using	Chi-	squared	for	categorical	variables,	and	t	test	or	ANOVA	for	
continuous	variables,	with	 their	 correspondent	nonparametric	 test	 if	
needed,	was	performed	to	compare	groups.	Poisson	regression	models	
with	robust	variance	were	estimated	to	obtain	a	crude	prevalence	ratio	
(PRc)	of	CRF	according	to	AEDs	prescription	and	etiology.	The	EIAED	
group	included	CBZ,	PHT,	PB,	and	primidone.	VPA	was	considered	the	
reference	drug	as	it	has	the	lowest	CRF	PRc	in	the	bivariate	analysis.	
Adjusted	PRs	(PRa)	for	variables	that	were	statistically	significant	in	the	
bivariate	analysis	(age,	sex,	duration	and	etiology	of	epilepsy,	and	AED	
therapy)	were	then	estimated	in	a	multivariate	model.	Adding	smoking	
did	not	change	the	magnitude	of	the	PR.	In	order	to	get	a	parsimonious	
model,	smoking	was	not	included	in	the	logistic	regression	due	to	the	
small	number	of	smokers	in	the	monotherapy	cohort.	To	obtain	stable	
PR	estimates,	only	drugs	prescribed	in	more	than	50	patients	and	data	
from	PWE	receiving	monotherapy	were	considered.	First,	CRF	preva-
lence	was	compared	between	patients	treated	with	EIAEDs	and	those	
taking	non-	EIAEDs.	The	analysis	was	then	repeated,	defining	the	group	
of	patients	treated	with	VPA	as	the	reference	group	and	considering	
CRF	prevalence	according	to	each	selected	AED.	A	sensitivity-	adjusted	
analysis	 was	 also	 performed,	 excluding	 patients	 with	 vascular	 etiol-
ogy,	considered	likely	to	be	the	main	contributors	to	the	CRF	burden.	
Patients	with	 cardiovascular	 events	 prior	 to	 receiving	 their	 epilepsy	
diagnosis	were	also	excluded,	for	the	same	reason.	A	p	value	<.05	was	
set	to	 indicate	statistical	significance.	STATA	v.12	statistical	package	
(StataCorp.	2001.	Statistical	Software:	Release	12.0;	Stata	Corporation,	
College	Station,	TX,	USA)	was	used	to	perform	the	analysis.
3  | RESULTS
Over	 a	 period	 of	 10	years,	 1,543	 patients	 were	 included	 con-
secutively	 in	 the	 register,	 of	 which	 1,045	 were	 aged	 35	years	
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or	 older	 and	 included	 in	 the	 present	 analysis.	 The	 flowchart	 of	
patients	included	in	the	register	and	in	the	final	analysis	is	shown	
in	Figure	1.
Median	age	was	52.53	years	(IQR:	42.60–66.11).	The	most	prev-
alent	etiology	was	structural/metabolic	 (519,	49.67%).	Patients	with	
genetic	epilepsy	were	younger	and	had	a	lower	prevalence	of	hyper-
tension,	dyslipidemia,	and	diabetes,	compared	to	patients	with	struc-
tural	and	unknown	etiologies	(Table	1).
3.1 | Cardiovascular risk factors and AEDs
Only	patients	under	monotherapy	(n	=	488)	and	drugs	prescribed	in	
more	than	50	patients	were	considered.	Results	from	the	bivariate	
analysis	are	summarized	 in	Table	2.	Multivariate	analysis,	adjusted	
by	age,	sex,	etiology	(genetic	as	reference),	and	epilepsy	duration,	
showed	 that	 patients	 receiving	 EIAEDs	 had	 36%	 higher	 preva-
lence	of	dyslipidemia,	compared	to	those	taking	non-	EIAEDs.	Only	
patients	 receiving	PHT	 showed	a	 significantly	 higher	dyslipidemia	
prevalence,	 compared	 to	 patients	 under	VPA	 (reference)	 therapy.	
After	 excluding	 vascular	 etiology	 and	 previous	 cardiovascular	
events,	 in	 the	 remaining	400	patients,	EIAEDs	 (PRa	1.45,	p	<	.05),	
and	 especially	 PHT	 (PRa	 1.77,	 p	<	.05),	 were	 still	 associated	with	
dyslipidemia	(Table	3).
3.2 | Cardiovascular risk factors and 
epilepsy etiology
Results	 from	 the	 bivariate	 analysis	 are	 shown	 in	 Figure	2,	 Panel	 a	
(left).	Multivariate	analysis	adjusted	by	age,	 sex,	AED	monotherapy,	
and	epilepsy	duration	showed	a	significant	association	between	etiol-
ogy	and	hypertension	(Figure	2,	Panel	a,	right).	After	excluding	vascu-
lar	etiology	or	previous	cardiovascular	events,	 the	 relation	between	
hypertension	and	etiology	 lost	 its	 statistical	 significance,	although	a	
positive	 trend	 (PRa	 2.11,	 95%	 CI	 0.88–5.04	 for	 structural	 etiology	
and	PRa	2.33,	95%	CI	0.97–5.57	for	unknown	etiology)	was	observed	
(Figure	2,	Panel	b).
F IGURE  1 Flowchart	showing	patients	
included	in	the	register	and	in	the	final	
analysis
TABLE  1 Descriptive	analysis	of	demographic	and	clinical	data:	total	sample	and	by	etiology
Total (N = 1,045)
Genetic (N = 123, 
11.77%)
Structural/metabolic (N = 519, 
49.67%)
Unknown (N = 403, 
38.56%) p value
Median	age	in	
years	at	
inclusion	(IQR)
52.53	(42.60–66.11) 43.8	(39.8–54.04) 53.17	(43.66–67.37) 54.96	(42.94–69.24) <.001
Women,	N	(%) 478	(45.74) 62	(50.41) 220	(42.39) 196	(48.64) .091
Median	epilepsy	
duration	in	
years	(IQR)
15.15	(1.975–33.85) 27.26	(15.23–37.22) 7.91	(0.86–28.84) 20.95	(4.92–37.11) <.001
HTA,	N	(%) 342	(32.73) 15	(12.20) 193	(37.19) 134	(33.25) <.001
DLP,	N	(%) 401	(38.37) 32	(26.02) 196	(37.76) 173	(42.93) .003
DM,	N	(%) 137	(13.11) 7	(5.69) 83	(15.99) 47	(11.66) .005
Smoking 228	(21.8) 28	(22.76) 121	(23.31) 79	(19.60) .143
IQR,	interquartile	range;	AED,	antiepileptic	drug;	HTA,	hypertension;	DLP,	dyslipidemia;	DM,	diabetes	mellitus.
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4  | DISCUSSION
Our	 study	 showed	 that	 dyslipidemia	 was	 the	 most	 frequent	 CRF	
and	its	presence	was	associated	with	EIAED	therapy.	A	recent	sys-
tematic	review	(Vyas	et	al.,	2015)	found	that	the	three	drugs	mostly	
related	to	changes	in	lipid	profile	are	PHT,	CBZ,	and	VPA.	In	our	case,	
EIAEDs—as	 a	 group—were	 associated	with	 dyslipidemia	 diagnosis.	
However,	only	patients	under	PHT	therapy	had	a	higher	prevalence	
of	 this	 CRF	 compared	 to	 those	 treated	with	 VPA.	 No	 differences	
were	 found	between	patients	 treated	with	CBZ	 and	 those	 receiv-
ing	VPA.	Although	we	cannot	discard	the	possibility	that	CBZ	might	
have	caused	changes	in	cholesterol	levels,	the	clinical	significance	is	
questionable,	as	any	changes	that	occurred	did	not	exceed	the	dys-
lipidemia	definition	threshold	(De	Backer	et	al.,	2003).	We	consider	
this	an	important	finding,	as	a	systematic	review	(Vyas	et	al.,	2015)	
reported	changes	in	lipid	profile	(i.e.,	an	increase	in	total	cholesterol	
from	180	to	190	mg/dl)	 that	did	not	necessarily	result	 in	a	dyslipi-
demia	diagnosis,	making	it	difficult	to	assess	prevalence	of	this	CRF,	
and	there	was	no	consistency	in	association	between	VPA	and	total	
cholesterol	 levels.	 In	 our	 study,	 patients	 under	VPA	 therapy	were	
less	 affected	 by	 dyslipidemia	 than	 the	 rest	 of	 the	 population.	We	
would	 speculate	 that	 the	 variety	 of	 lipid	 profile	 findings	 analyzed	
in	 the	systematic	 review	might	correspond	 to	differences	not	only	
in	 the	study	design	 (Grau	et	al.,	2007)	but	also	 in	 the	geographical	
region	or	dietary	habits.	Concerning	new	AEDs,	we	observed	 that	
the	levetiracetam	group	had	more	CRFs,	compared	to	patient	groups	
taking	 other	 drugs	 (in	monotherapy).	 However,	 after	 adjusting	 for	
several	 factors,	 the	 significance	of	 the	association	disappeared.	As	
this	was	a	cross-	sectional	 study,	 that	 result	might	be	explained	by	
selection	 bias	 if	 patients	 had	 these	 CRFs	 before	 beginning	 leveti-
racetam	therapy.
TABLE  2 Crude	and	adjusted	prevalence	ratio	of	cardiovascular	risk	factors	according	to	the	prescription	of	antiepileptic	drugs,	in	patients	
under	monotherapy
HTA DLP DM
N (%) PRc (95% CI)
PRa (95% 
CI) N (%) PRc (95% CI) PRa (95% CI) N (%) PRc (95% CI) PRa (95% CI)
Inducer	vs	noninducers	AEDs
Inducer	AEDs	
(N	=	185)
59	(31.89) 0.79	
(0.62–1.02)
0.88 
(0.69–1.11)
82	(44.32) 1.33	*	
(1.06–1.67)
1.36	*	
(1.07–1.72)
18	(9.73) 0.51	*	
(0.31–0.84)
0.73	
(0.45–1.19)
Individual	AEDs	with	VPA	as	reference	group
CBZ	(N	=	86) 21	(24.42) 0.76 
(0.49–1.17)
0.71 
(0.47–1.06)
31	(36.05) 1.41 
(0.96–2.07)
1.28 
(0.87–1.90)
6	(6.98) 0.44 
(0.19–1.03)
0.65	
(0.26–1.59)
PHT	(N	=	70) 31	(44.29) 1.37	
(0.97–1.93)
1.04 
(0.77–1.39)
37	(52.86) 2.06*	
(1.47–2.91)
1.72*	
(1.22–2.44)
8	(11.43) 0.72 
(0.34–1.51)
0.65	
(0.33–1.28)
LEV	(N	=	139) 69	(49.64) 1.54	*	
(1.16–2.03)
1.02 
(0.81–1.30)
59	(42.45) 1.66*	
(1.20–2.29)
1.33	
(0.96–1.84)
32	(23.02) 1.45	
(0.91–2.31)
0.96	
(0.61–1.50)
VPA	(N	=	164) 53	(32.52) 1 1 42	(25.61) 1 1 26	(15.85) 1 1
Model	adjusted	by	age,	sex,	etiology	(genetic	as	a	reference),	and	epilepsy	duration.	HTA,	hypertension;	DLP,	dyslipidemia;	DM,	diabetes	mellitus;	PRc,	
prevalence	ratio,	crude;	PRa,	prevalence	ratio,	adjusted;	CBZ,	carbamazepine;	PHT,	phenytoin;	LEV,	levetiracetam;	VPA,	valproic	acid.
*Statistically	significant	p	<	.05.
TABLE  3 Adjusted	prevalence	ratio	of	cardiovascular	risk	factors	according	to	the	prescription	of	antiepileptic	drugs,	in	patients	under	
monotherapy	and	without	vascular	epilepsy	or	cardiovascular	events	previous	to	diagnosis
HTA DLP DM
N (%) PRa N (%) PRa N (%) PRa
Inducer	vs	noninducers	AEDs
Inducer	AEDs	(155) 35	(22.58) 0.81	(0.58–1.13) 58	(37.42) 1.45	*	(1.09–1.92) 11	(7.10) 0.77	(0.40–1.48)
Individual	AEDs	with	VPA	as	reference	group
CBZ	(77) 14	(18.18) 0.69	(0.40–1.18) 24	(31.17) 1.25	(0.78–2) 5	(6.49) 1.00	(0.33–3.07)
PHT	(54) 18	(33.33) 1.07	(0.70–1.64) 25	(46.30) 1.77*	(1.15–2.73) 3	(5.56) 0.61	(0.19–1.97)
LEV	(102) 41	(40.20) 1.12	(0.79–1.58) 37	(36.27) 1.36	(0.91–2.04) 17	(16.67) 1.32	(0.65–2.67)
VPA	(143) 34	(23.78) 1 32	(22.38) 1 13	(9.09) 1
Model	adjusted	by	age,	sex,	and	epilepsy	duration.	In	the	case	of	hypertension,	adjusted	also	by	etiology	(genetic	as	a	reference).	HTA,	hypertension;	DLP,	
dyslipidemia;	DM,	diabetes	mellitus;	PRa,	prevalence	ratio	adjusted;	CBZ,	carbamazepine;	PHT,	phenytoin;	LEV,	levetiracetam;	VPA,	valproic	acid.
*Statistically	significant	p	<	.05.
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Another	interesting	result	was	the	low	prevalence	of	diabetes	in	the	
EIAEDs	group.	Inconsistent	results	in	the	literature	make	us	cautious	
about	 the	 interpretation	of	 this	 finding.	 In	 the	past	 (Vaisrub,	 1973),	
PHT	was	reported	to	be	related	to	hyperglycemia	and	reduced	insu-
lin	response	in	patients	with	glucose	intolerance.	However,	we	found	
no	studies	analyzing	diabetes	prevalence	or	showing	that	PHT,	CBZ,	
or	other	EIAEDs	cause	diabetes	mellitus.	More	studies	are	needed	to	
compare	diabetes	prevalence	(the	least	prevalent	CRF)	in	this	popula-
tion	to	a	general	population	without	EIAEDs	therapy.
Etiology	 has	 been	 reported	 to	 play	 a	 role	 in	 the	 relationship	
between	epilepsy	and	CRF	prevalence.	In	our	analysis,	the	lowest	prev-
alence	of	CRF	was	associated	with	genetic	etiology.	A	recent	review	
(Gaitatzis	et	al.,	2012)	reported	high	prevalence	of	CRFs	in	PWE	and	
suggested	that	this	is	more	likely	a	cause	than	a	result	of	epilepsy,	as	
they	 increase	 the	 risk	of	 stroke,	which	 is	 a	 cause	of	epilepsy.	 In	our	
initial	analysis,	structural	and	unknown	etiology	were	associated	with	
higher	prevalence	of	all	three	risk	factors,	compared	to	genetic	etiol-
ogy.	 In	 the	multivariate	 analysis,	 however,	 this	 association	 remained	
only	for	hypertension.	After	excluding	vascular	epilepsy	and	previous	
cardiovascular	 events,	 this	 association	 disappeared.	 Thus,	 we	 con-
cluded	that	our	findings	were	related	to	vascular	events	previous	to	the	
epilepsy	diagnosis	and	not	to	epilepsy	itself.	Despite	this	 lack	of	sta-
tistical	significance,	the	trend	showing	more	hypertension	in	patients	
with	structural	and	unknown	etiology	leads	us	to	conclude	that	more	
studies	are	needed	to	clarify	a	finding	that	could	be	clinically	relevant.
4.1 | Limitations
As	this	was	a	cross-	sectional	study,	we	could	not	establish	any	causal	
relationship	between	AEDs	and	CRF.	We	assumed	a	selection	bias	in	
treatment	indication.	For	instance,	levetiracetam	is	not	related	to	drug	
interactions	and	therefore	might	have	been	prescribed	in	patients	with	
more	previous	comorbidities.	Another	limitation	was	the	sample	size	
for	the	PR	assessment.	To	give	strength	to	the	observed	association	
and	avoid	mixing	the	effects	of	polytherapy,	we	selected	only	patients	
receiving	 monotherapy.	 The	 choice	 of	 VPA	 as	 a	 reference	 AED	 is	
another	potential	 limitation,	as	VPA	has	been	associated	with	meta-
bolic	syndrome	(Kim	&	Lee,	2007).	More	recent	studies	have	called	the	
F IGURE  2 Results	from	the	bivariate	analysis.	Panel	(a):	Crude	and	adjusted	prevalence	ratio	of	cardiovascular	risk	factors	according	to	
etiology	and	95%	confidence	interval,	in	patients	under	monotherapy.	Model	adjusted	by	age,	sex,	epilepsy	duration,	antiepileptic	drugs	(AEDs).	
HTA,	hypertension;	DLP,	dyslipidemia;	DM	diabetes	mellitus.	Panel	(b):	Adjusted	prevalence	ratio	of	cardiovascular	risk	factors	according	
to	etiology	and	95%	confidence	interval,	in	patients	under	monotherapy	and	without	vascular	epilepsy	or	cardiovascular	events	previous	to	
diagnosis.	Model	adjusted	by	age,	sex,	epilepsy	duration,	AEDs	
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association	into	question,	as	this	trend	was	not	replicable	in	a	recent	
population	study	 (Rakitin	et	al.,	2014)	and	did	not	differ	 from	other	
AEDs	such	as	CBZ	in	another	report	(Rakitin,	Kõks,	&	Haldre,	2016).	In	
our	study,	VPA	had	the	lowest	CRF	PRc,	and	taking	into	account	these	
recently	published	results,	we	considered	that	using	it	as	the	reference	
AED	would	not	cause	major	confusion.	Our	analysis	was	not	adjusted	
by	body	mass	index	or	socioeconomic	status,	as	we	did	not	have	access	
to	this	information.	We	do	not	consider	this	a	major	limitation,	given	
the	 established	 relationship	 between	 these	 two	 indicators,	 because	
our	reference	population	(Ciutat	Vella	and	Sant	Marti	district)	is	very	
homogeneous	in	its	socioeconomic	profile	(Barcelona	Department	of	
Statistics,	2016).	In	summary,	treatment	with	EIAEDs,	especially	PHT,	
in	PWE	is	associated	with	higher	prevalence	of	dyslipidemia,	but	not	
with	 other	 CRFs.	 After	 excluding	 vascular	 etiology,	 there	 were	 no	
differences	 in	CRF	prevalence	between	etiologies,	 although	a	 trend	
toward	higher	prevalence	of	hypertension	was	observed	in	structural	
and	unknown	etiologies,	compared	to	genetic	epilepsy.	Further	stud-
ies	 are	 needed	 to	 elucidate	 whether	 these	 results	 translate	 into	 a	
higher	cardiovascular	risk	profile	and	therefore	higher	cardiovascular	
disease	incidence	in	our	study	population.
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